Loading…
Simultaneous Transdermal Delivery of Buprenorphine Hydrochloride and Naltrexone Hydrochloride by Iontophoresis
The opioids buprenorphine hydrochloride (BUP) and naltrexone hydrochloride (NTX) show promise as a combination treatment for addiction, but no means of delivering the two compounds in one medicine currently exist. In this paper, we report sufficient input rates of both these drugs from one iontophor...
Saved in:
Published in: | Molecular pharmaceutics 2019-06, Vol.16 (6), p.2808-2816 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-a480t-4e09aec6baafcd97d79282ae09000921e12fe8b7c7509dd58b7fb65fabd74c0f3 |
---|---|
cites | cdi_FETCH-LOGICAL-a480t-4e09aec6baafcd97d79282ae09000921e12fe8b7c7509dd58b7fb65fabd74c0f3 |
container_end_page | 2816 |
container_issue | 6 |
container_start_page | 2808 |
container_title | Molecular pharmaceutics |
container_volume | 16 |
creator | Cordery, Sarah F Husbands, Stephen M Bailey, Christopher P Guy, Richard H Delgado-Charro, M. Begoña |
description | The opioids buprenorphine hydrochloride (BUP) and naltrexone hydrochloride (NTX) show promise as a combination treatment for addiction, but no means of delivering the two compounds in one medicine currently exist. In this paper, we report sufficient input rates of both these drugs from one iontophoretic transdermal drug delivery system. Experiments were performed using dermatomed pig skin mounted in glass side-bi-side cells. BUP and NTX were iontophoretically delivered together from the anode using direct constant current from Ag/AgCl electrodes. The transdermal drug fluxes and the masses of drugs in both the stratum corneum and the underlying epidermis/dermis were measured. The apparent electroosmotic flow was quantified using a neutral marker (acetaminophen). The effects of donor composition (drug concentration/molar fraction and pH), current density and profile, and the choice of receptor solution were assessed. Iontophoresis dramatically increased the flux of both drugs compared to passive control values. Target fluxes (calculated from literature clearance values and required therapeutic plasma concentrations) were greatly exceeded for NTX and were met for BUP. The latter accumulated in the skin and suppressed electroosmotic flow, inhibiting both its own flux and that of NTX. NTX, in turn, negatively influenced the flux of BUP via co-ion competition. Lowering current density by increasing the delivery area resulted in increased electroosmotic flow but did not significantly affect current-normalized drug fluxes. Delivering the drugs from both electrodes and reversing the polarity for every 2 h did not increase the flux of either compound. In summary, during iontophoresis, BUP and NTX inhibited each other’s flux by two distinct mechanisms. While the more complex behavior of BUP complicates the optimization of this drug combination, iontophoresis nevertheless appears to be a feasible approach for the controlled codelivery of NTX and BUP through the skin. |
doi_str_mv | 10.1021/acs.molpharmaceut.9b00337 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2231930339</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2231930339</sourcerecordid><originalsourceid>FETCH-LOGICAL-a480t-4e09aec6baafcd97d79282ae09000921e12fe8b7c7509dd58b7fb65fabd74c0f3</originalsourceid><addsrcrecordid>eNqNkE1PwzAMhiMEYmPwF1C5cenIR7s2RxgfmzTBgXGu0sRVO6VNSVpE_z2ZOpAQF0627Nev7QehK4LnBFNyI6Sb10a3pbC1kNB3c55jzFhyhKYkjliYMk6Pf_I0mqAz53YY0yim7BRNGMEJ5jSZoua1qnvdiQZM74KtFY1T4F11cA-6-gA7BKYI7vrWQmNsW1YNBKtBWSNLbWylIBCNCp6F7ix8mj_NfAjWpulMWxoLrnLn6KQQ2sHFIc7Q2-PDdrkKNy9P6-XtJhRRirswAswFyEUuRCEVT1TCaUqFr2Ls7yZAaAFpnsgkxlyp2KdFvogLkaskkrhgM3Q9-rbWvPfguqyunAStx0czShnhzCPjXspHqbTGOQtF1tqqFnbICM72uDOPO_uFOzvg9rOXhzV9XoP6mfzm6wXxKNh77ExvG__1P4y_AFf5l_M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2231930339</pqid></control><display><type>article</type><title>Simultaneous Transdermal Delivery of Buprenorphine Hydrochloride and Naltrexone Hydrochloride by Iontophoresis</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)</source><creator>Cordery, Sarah F ; Husbands, Stephen M ; Bailey, Christopher P ; Guy, Richard H ; Delgado-Charro, M. Begoña</creator><creatorcontrib>Cordery, Sarah F ; Husbands, Stephen M ; Bailey, Christopher P ; Guy, Richard H ; Delgado-Charro, M. Begoña</creatorcontrib><description>The opioids buprenorphine hydrochloride (BUP) and naltrexone hydrochloride (NTX) show promise as a combination treatment for addiction, but no means of delivering the two compounds in one medicine currently exist. In this paper, we report sufficient input rates of both these drugs from one iontophoretic transdermal drug delivery system. Experiments were performed using dermatomed pig skin mounted in glass side-bi-side cells. BUP and NTX were iontophoretically delivered together from the anode using direct constant current from Ag/AgCl electrodes. The transdermal drug fluxes and the masses of drugs in both the stratum corneum and the underlying epidermis/dermis were measured. The apparent electroosmotic flow was quantified using a neutral marker (acetaminophen). The effects of donor composition (drug concentration/molar fraction and pH), current density and profile, and the choice of receptor solution were assessed. Iontophoresis dramatically increased the flux of both drugs compared to passive control values. Target fluxes (calculated from literature clearance values and required therapeutic plasma concentrations) were greatly exceeded for NTX and were met for BUP. The latter accumulated in the skin and suppressed electroosmotic flow, inhibiting both its own flux and that of NTX. NTX, in turn, negatively influenced the flux of BUP via co-ion competition. Lowering current density by increasing the delivery area resulted in increased electroosmotic flow but did not significantly affect current-normalized drug fluxes. Delivering the drugs from both electrodes and reversing the polarity for every 2 h did not increase the flux of either compound. In summary, during iontophoresis, BUP and NTX inhibited each other’s flux by two distinct mechanisms. While the more complex behavior of BUP complicates the optimization of this drug combination, iontophoresis nevertheless appears to be a feasible approach for the controlled codelivery of NTX and BUP through the skin.</description><identifier>ISSN: 1543-8384</identifier><identifier>EISSN: 1543-8392</identifier><identifier>DOI: 10.1021/acs.molpharmaceut.9b00337</identifier><identifier>PMID: 31070927</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Acetaminophen - chemistry ; Buprenorphine - chemistry ; Drug Delivery Systems - methods ; Hydrogen-Ion Concentration ; Iontophoresis ; Naltrexone - chemistry</subject><ispartof>Molecular pharmaceutics, 2019-06, Vol.16 (6), p.2808-2816</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a480t-4e09aec6baafcd97d79282ae09000921e12fe8b7c7509dd58b7fb65fabd74c0f3</citedby><cites>FETCH-LOGICAL-a480t-4e09aec6baafcd97d79282ae09000921e12fe8b7c7509dd58b7fb65fabd74c0f3</cites><orcidid>0000-0002-2233-7654 ; 0000-0003-3227-9862</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31070927$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cordery, Sarah F</creatorcontrib><creatorcontrib>Husbands, Stephen M</creatorcontrib><creatorcontrib>Bailey, Christopher P</creatorcontrib><creatorcontrib>Guy, Richard H</creatorcontrib><creatorcontrib>Delgado-Charro, M. Begoña</creatorcontrib><title>Simultaneous Transdermal Delivery of Buprenorphine Hydrochloride and Naltrexone Hydrochloride by Iontophoresis</title><title>Molecular pharmaceutics</title><addtitle>Mol. Pharmaceutics</addtitle><description>The opioids buprenorphine hydrochloride (BUP) and naltrexone hydrochloride (NTX) show promise as a combination treatment for addiction, but no means of delivering the two compounds in one medicine currently exist. In this paper, we report sufficient input rates of both these drugs from one iontophoretic transdermal drug delivery system. Experiments were performed using dermatomed pig skin mounted in glass side-bi-side cells. BUP and NTX were iontophoretically delivered together from the anode using direct constant current from Ag/AgCl electrodes. The transdermal drug fluxes and the masses of drugs in both the stratum corneum and the underlying epidermis/dermis were measured. The apparent electroosmotic flow was quantified using a neutral marker (acetaminophen). The effects of donor composition (drug concentration/molar fraction and pH), current density and profile, and the choice of receptor solution were assessed. Iontophoresis dramatically increased the flux of both drugs compared to passive control values. Target fluxes (calculated from literature clearance values and required therapeutic plasma concentrations) were greatly exceeded for NTX and were met for BUP. The latter accumulated in the skin and suppressed electroosmotic flow, inhibiting both its own flux and that of NTX. NTX, in turn, negatively influenced the flux of BUP via co-ion competition. Lowering current density by increasing the delivery area resulted in increased electroosmotic flow but did not significantly affect current-normalized drug fluxes. Delivering the drugs from both electrodes and reversing the polarity for every 2 h did not increase the flux of either compound. In summary, during iontophoresis, BUP and NTX inhibited each other’s flux by two distinct mechanisms. While the more complex behavior of BUP complicates the optimization of this drug combination, iontophoresis nevertheless appears to be a feasible approach for the controlled codelivery of NTX and BUP through the skin.</description><subject>Acetaminophen - chemistry</subject><subject>Buprenorphine - chemistry</subject><subject>Drug Delivery Systems - methods</subject><subject>Hydrogen-Ion Concentration</subject><subject>Iontophoresis</subject><subject>Naltrexone - chemistry</subject><issn>1543-8384</issn><issn>1543-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqNkE1PwzAMhiMEYmPwF1C5cenIR7s2RxgfmzTBgXGu0sRVO6VNSVpE_z2ZOpAQF0627Nev7QehK4LnBFNyI6Sb10a3pbC1kNB3c55jzFhyhKYkjliYMk6Pf_I0mqAz53YY0yim7BRNGMEJ5jSZoua1qnvdiQZM74KtFY1T4F11cA-6-gA7BKYI7vrWQmNsW1YNBKtBWSNLbWylIBCNCp6F7ix8mj_NfAjWpulMWxoLrnLn6KQQ2sHFIc7Q2-PDdrkKNy9P6-XtJhRRirswAswFyEUuRCEVT1TCaUqFr2Ls7yZAaAFpnsgkxlyp2KdFvogLkaskkrhgM3Q9-rbWvPfguqyunAStx0czShnhzCPjXspHqbTGOQtF1tqqFnbICM72uDOPO_uFOzvg9rOXhzV9XoP6mfzm6wXxKNh77ExvG__1P4y_AFf5l_M</recordid><startdate>20190603</startdate><enddate>20190603</enddate><creator>Cordery, Sarah F</creator><creator>Husbands, Stephen M</creator><creator>Bailey, Christopher P</creator><creator>Guy, Richard H</creator><creator>Delgado-Charro, M. Begoña</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2233-7654</orcidid><orcidid>https://orcid.org/0000-0003-3227-9862</orcidid></search><sort><creationdate>20190603</creationdate><title>Simultaneous Transdermal Delivery of Buprenorphine Hydrochloride and Naltrexone Hydrochloride by Iontophoresis</title><author>Cordery, Sarah F ; Husbands, Stephen M ; Bailey, Christopher P ; Guy, Richard H ; Delgado-Charro, M. Begoña</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a480t-4e09aec6baafcd97d79282ae09000921e12fe8b7c7509dd58b7fb65fabd74c0f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acetaminophen - chemistry</topic><topic>Buprenorphine - chemistry</topic><topic>Drug Delivery Systems - methods</topic><topic>Hydrogen-Ion Concentration</topic><topic>Iontophoresis</topic><topic>Naltrexone - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cordery, Sarah F</creatorcontrib><creatorcontrib>Husbands, Stephen M</creatorcontrib><creatorcontrib>Bailey, Christopher P</creatorcontrib><creatorcontrib>Guy, Richard H</creatorcontrib><creatorcontrib>Delgado-Charro, M. Begoña</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cordery, Sarah F</au><au>Husbands, Stephen M</au><au>Bailey, Christopher P</au><au>Guy, Richard H</au><au>Delgado-Charro, M. Begoña</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Simultaneous Transdermal Delivery of Buprenorphine Hydrochloride and Naltrexone Hydrochloride by Iontophoresis</atitle><jtitle>Molecular pharmaceutics</jtitle><addtitle>Mol. Pharmaceutics</addtitle><date>2019-06-03</date><risdate>2019</risdate><volume>16</volume><issue>6</issue><spage>2808</spage><epage>2816</epage><pages>2808-2816</pages><issn>1543-8384</issn><eissn>1543-8392</eissn><abstract>The opioids buprenorphine hydrochloride (BUP) and naltrexone hydrochloride (NTX) show promise as a combination treatment for addiction, but no means of delivering the two compounds in one medicine currently exist. In this paper, we report sufficient input rates of both these drugs from one iontophoretic transdermal drug delivery system. Experiments were performed using dermatomed pig skin mounted in glass side-bi-side cells. BUP and NTX were iontophoretically delivered together from the anode using direct constant current from Ag/AgCl electrodes. The transdermal drug fluxes and the masses of drugs in both the stratum corneum and the underlying epidermis/dermis were measured. The apparent electroosmotic flow was quantified using a neutral marker (acetaminophen). The effects of donor composition (drug concentration/molar fraction and pH), current density and profile, and the choice of receptor solution were assessed. Iontophoresis dramatically increased the flux of both drugs compared to passive control values. Target fluxes (calculated from literature clearance values and required therapeutic plasma concentrations) were greatly exceeded for NTX and were met for BUP. The latter accumulated in the skin and suppressed electroosmotic flow, inhibiting both its own flux and that of NTX. NTX, in turn, negatively influenced the flux of BUP via co-ion competition. Lowering current density by increasing the delivery area resulted in increased electroosmotic flow but did not significantly affect current-normalized drug fluxes. Delivering the drugs from both electrodes and reversing the polarity for every 2 h did not increase the flux of either compound. In summary, during iontophoresis, BUP and NTX inhibited each other’s flux by two distinct mechanisms. While the more complex behavior of BUP complicates the optimization of this drug combination, iontophoresis nevertheless appears to be a feasible approach for the controlled codelivery of NTX and BUP through the skin.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>31070927</pmid><doi>10.1021/acs.molpharmaceut.9b00337</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-2233-7654</orcidid><orcidid>https://orcid.org/0000-0003-3227-9862</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1543-8384 |
ispartof | Molecular pharmaceutics, 2019-06, Vol.16 (6), p.2808-2816 |
issn | 1543-8384 1543-8392 |
language | eng |
recordid | cdi_proquest_miscellaneous_2231930339 |
source | American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list) |
subjects | Acetaminophen - chemistry Buprenorphine - chemistry Drug Delivery Systems - methods Hydrogen-Ion Concentration Iontophoresis Naltrexone - chemistry |
title | Simultaneous Transdermal Delivery of Buprenorphine Hydrochloride and Naltrexone Hydrochloride by Iontophoresis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T02%3A48%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Simultaneous%20Transdermal%20Delivery%20of%20Buprenorphine%20Hydrochloride%20and%20Naltrexone%20Hydrochloride%20by%20Iontophoresis&rft.jtitle=Molecular%20pharmaceutics&rft.au=Cordery,%20Sarah%20F&rft.date=2019-06-03&rft.volume=16&rft.issue=6&rft.spage=2808&rft.epage=2816&rft.pages=2808-2816&rft.issn=1543-8384&rft.eissn=1543-8392&rft_id=info:doi/10.1021/acs.molpharmaceut.9b00337&rft_dat=%3Cproquest_cross%3E2231930339%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a480t-4e09aec6baafcd97d79282ae09000921e12fe8b7c7509dd58b7fb65fabd74c0f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2231930339&rft_id=info:pmid/31070927&rfr_iscdi=true |